ProShares Ultra Nasdaq Biotechnology (BIB) Short Interest Ratio & Short Volume

Short interest is the volume of ProShares Ultra Nasdaq Biotechnology shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 7,600 shares of BIB short. Learn More on ProShares Ultra Nasdaq Biotechnology's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. BIB shares currently have a short interest ratio of 1.0. Learn More on ProShares Ultra Nasdaq Biotechnology's short interest ratio.

ProShares Ultra Nasdaq Biotechnology saw a decrease in short interest in October. As of October 31st, there was short interest totaling 7,600 shares, a decrease of 54.8% from the previous total of 16,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies compare to ProShares Ultra Nasdaq Biotechnology: Invesco Nasdaq Biotechnology ETF (0.89%), Invesco Dorsey Wright Healthcare Momentum ETF (0.03%), First Trust Nasdaq Pharmaceuticals ETF (0.48%), JPMorgan Healthcare Leaders ETF (1.31%), ProShares UltraShort Nasdaq Biotechnology (2.95%), Invesco S&P SmallCap Health Care ETF (0.00%), VanEck Biotech ETF (0.02%), VanEck Pharmaceutical ETF (25.17%), and iShares Biotechnology ETF (20.20%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling BIB is an investing strategy that aims to generate trading profit from ProShares Ultra Nasdaq Biotechnology as its price is falling. BIB shares are trading down $5.31 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for ProShares Ultra Nasdaq Biotechnology occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BIB, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BIB, twice per month. The most recent reporting period available is October, 31 2024.